한글목차

대사 이상 치료제 세계 시장 규모는 2024년 744억 달러에 달했고, 2030년까지 예측 기간 동안 연평균 7.68%의 괄목할 만한 성장을 보일 것으로 예상됩니다.

대사 이상 치료제 세계 시장에는 대사 이상에 대한 표적 치료법 개발에 주력하는 제약 및 생명공학 산업이 포함됩니다. 이러한 질환은 필수 영양소를 처리하고 조절하는 신체의 능력을 방해하는 것으로, 당뇨병, 비만, 고지혈증과 같은 광범위한 질환뿐만 아니라 페닐케톤뇨증, 고셔병과 같은 희귀한 유전성 질환도 포함됩니다.

유전자 치료, 효소 보충 요법, 차세대 체중 감량 약물과 같은 표적 치료법의 발전과 함께 전 세계 대사성 질환의 유병률 증가가 시장 성장을 견인하고 있습니다. 주요 제약사들은 연구개발과 전략적 제휴에 많은 투자를 하고 있습니다.

그러나 이 분야에서 사업을 전개하는 기업들은 상업적 잠재력을 극대화하기 위해 규제의 복잡성, 엄격한 임상 승인 절차, 장기적인 안전성에 대한 우려를 해결해야 합니다. 과학적 혁신과 규제 준수를 잘 융합하는 기업들은 대사 이상 치료제 수요 증가에 유리한 고지를 점할 수 있을 것으로 보입니다.

주요 시장 성장 촉진요인

대사 이상 유병률 증가

주요 시장 이슈

높은 개발 비용

주요 시장 동향

정밀의료와 맞춤치료

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 대사장애 치료제 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 질환 유형별(리소좀 축적증, 당뇨병, 비만, 유전성 대사질환, 고콜레스테롤혈증, 기타)
  • 치료 유형별(효소 보충 요법, 세포 이식, 소분자 요법, 기질 감소 요법, 유전자 치료, 약물 요법)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 대사장애 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 대사장애 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 대사장애 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 대사장애 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 대사장애 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제13장 세계의 대사장애 치료제 시장 : SWOT 분석

제14장 경쟁 구도

• Novo Nordisk A/S
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• Merck KGaA
• AstraZeneca PLC
• AbbVie Inc
• Johnson & Johnson Services, Inc
• Amgen Inc
• BioMarin International Limited

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

영문목차

Global Metabolic Disorders Therapeutics Market was valued at USD 74.40 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.68% through 2030. The Global Metabolic Disorders Therapeutics Market encompasses the pharmaceutical and biotechnology industries focused on developing targeted treatments for metabolic disorders. These conditions, which disrupt the body's ability to process and regulate essential nutrients, include widespread diseases such as diabetes, obesity, and hyperlipidemia, as well as rare genetic disorders like phenylketonuria and Gaucher's disease.

Market growth is being propelled by the rising global incidence of metabolic diseases, coupled with advancements in targeted therapies, including gene therapy, enzyme replacement therapy, and next-generation weight-loss medications. Leading pharmaceutical firms are investing heavily in R&D and strategic collaborations.

However, companies operating in this sector must address regulatory complexities, stringent clinical approval processes, and long-term safety concerns to maximize commercial potential. Firms that successfully integrate scientific innovation with regulatory compliance will be well-positioned to capitalize on the expanding demand for metabolic disorder therapeutics.

Key Market Drivers

Rising Prevalence of Metabolic Disorders

The increasing global burden of metabolic disorders is a primary force accelerating the growth of the Global Metabolic Disorders Therapeutics Market. As the incidence of diseases such as diabetes, obesity, hyperlipidemia, and rare genetic metabolic disorders rises sharply, the demand for innovative therapeutics, disease management solutions, and preventive interventions continues to grow. Several factors contribute to this trend, each reinforcing the market's expansion and creating new opportunities for pharmaceutical and biotechnology companies.

According to the IDF Diabetes Atlas (2021), 10.5% of the global adult population (ages 20-79) is living with diabetes, with nearly 50% of cases remaining undiagnosed due to limited awareness and screening gaps. Projections indicate that by 2045, the prevalence will rise to 1 in 8 adults, reaching approximately 783 million cases-a 46% increase driven by shifting demographics, urbanization, and lifestyle changes. Notably, over 90% of diabetes cases are classified as Type 2 diabetes, largely influenced by socioeconomic disparities, aging populations, environmental risk factors, and genetic predisposition. This surge in global disease burden is expected to intensify demand for advanced therapeutics, early diagnostic solutions, and digital health interventions, making diabetes management a critical priority for healthcare systems and pharmaceutical innovators.

Key Market Challenges

High Development Costs

The research and development of new therapies for metabolic disorders can be prohibitively expensive. The cost of conducting clinical trials, obtaining regulatory approvals, and ensuring safety and efficacy adds significant financial pressure to pharmaceutical and biotech companies.

Key Market Trends

Precision Medicine and Personalized Therapies

The era of one-size-fits-all treatments is giving way to precision medicine. Genetic profiling, biomarker identification, and patient-specific data are increasingly guiding treatment decisions. Tailored therapies that consider an individual's genetic and metabolic profile promise higher efficacy and reduced side effects in the management of metabolic disorders.

Key Market Players

• Novo Nordisk A/S
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• Merck KGaA
• AstraZeneca PLC
• AbbVie Inc
• Johnson & Johnson Services, Inc
• Amgen Inc
• BioMarin International Limited

Report Scope:

In this report, the Global Metabolic Disorders Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolic Disorders Therapeutics Market, By Disease Type:

• Lysosomal Storage Diseases
• Diabetes
• Obesity
• Inherited Metabolic Disorders
• Hypercholesterolemia
• Others

Metabolic Disorders Therapeutics Market, By Therapy Type:

• Enzyme Replacement Therapy
• Cellular Transplantation
• Small Molecule Based Therapy
• Substrate Reduction Therapy
• Gene Therapy
• Drug Therapy

Metabolic Disorders Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolic Disorders Therapeutics Market.

Available Customizations:

Global Metabolic Disorders Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Metabolic Disorders Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
  • 5.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Metabolic Disorders Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metabolic Disorders Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy Type
  • 6.3.2. Canada Metabolic Disorders Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy Type
  • 6.3.3. Mexico Metabolic Disorders Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy Type

7. Europe Metabolic Disorders Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Metabolic Disorders Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy Type
  • 7.3.2. United Kingdom Metabolic Disorders Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy Type
  • 7.3.3. Italy Metabolic Disorders Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy Type
  • 7.3.4. France Metabolic Disorders Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy Type
  • 7.3.5. Spain Metabolic Disorders Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy Type

8. Asia-Pacific Metabolic Disorders Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy Type
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Metabolic Disorders Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy Type
  • 8.3.2. India Metabolic Disorders Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy Type
  • 8.3.3. Japan Metabolic Disorders Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy Type
  • 8.3.4. South Korea Metabolic Disorders Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy Type
  • 8.3.5. Australia Metabolic Disorders Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy Type

9. South America Metabolic Disorders Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy Type
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Metabolic Disorders Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy Type
  • 9.3.2. Argentina Metabolic Disorders Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy Type
  • 9.3.3. Colombia Metabolic Disorders Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy Type

10. Middle East and Africa Metabolic Disorders Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy Type
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Metabolic Disorders Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy Type
  • 10.3.2. Saudi Arabia Metabolic Disorders Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy Type
  • 10.3.3. UAE Metabolic Disorders Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Metabolic Disorders Therapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Novo Nordisk A/S
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Eli Lilly and Company
• 14.3. Takeda Pharmaceutical Company Limited
• 14.4. Sanofi SA
• 14.5. Merck KGaA
• 14.6. AstraZeneca PLC
• 14.7. AbbVie Inc
• 14.8. Johnson & Johnson Services, Inc
• 14.9. Amgen Inc
• 14.10.BioMarin International Limited

15. Strategic Recommendations

16. About Us & Disclaimer